预约演示
Diagonal launches with $128M and a platform slanted toward agonist antibodies
2024-04-03
并购上市批准抗体药物偶联物
Diagonal Therapeutics is building a pipeline of antibody agonists rather than receptor blockers.
Diagonal Therapeutics is taking shape, launching with $128 million and backed by the likes of BVF Partners, Atlas Venture and RA Capital to develop a pipeline of antibody agonists.
Diagonal Therapeuticsthis significant financial firepower to accelerate development of its pipeline of four Atlas Venturef these candidates are more advanced, including a lead asset targeting the inherited bleeding disorder hereditary hemorrhagic telangiectasia (HHT) and a runner-up designed to treat pulmonary arterial hypertension (PAH).
Unlike conventional antibody development, Diagonal is working on candidates that activate broken signaling pathways rather than inhibit them. The HHT asset, for example, reignites a receptor in thinherited bleeding disorderrhereditary hemorrhagic telangiectasia (HHT)ntibodies “prevent and reverse the pulmonary arterial hypertension (PAH)lformations,” the company said in a release.
The $128 million will pay for at least a proof-of-concept study for the HHT program, the company noted in its announcement, though a full cash runway was not specified.TGF-β
Diagonal is led by CEO Alex Lugovskoy, Ph.D., an entrepreneur-in-residence at Atlas who’s had previous C-suite stints at Dragonfly Therapeutics and Morphic Therapeutic. Diagonal's platform is the byproduct of computational and scientific advancements made in the last five to 10 years, Lugovskoy told Fierce Biotech.
“I think more and more people will start using those types of approaches to all kinds of antibody engineering techniques,Dragonfly TherapeuticsxperiMorphic Therapeuticional,” the CEO said in an interview.
Diagonal’s stated PAH ambitions come days after Merck & Co.’s much-hyped Winrevair (sotatercept) received FDA approval for the condition, resetting the competitive landscape. Lugovskoy conceded that unlike HHT, which lacks treatment options, Winrevair is a “significant advance” for PAH patients. But he said that because the drug acts as an activin receptor ligand trap rather than a fix for genetic mutations, the worst case scenario for Diagonal is that its own candidate—if approved—is synergistic on the marketplace.
Diagonalt see us dPAHctly competing with sotaterMerck & Co.e what we are Winrevairprsotaterceptsing signalFDA, whereas [Merck is] inhibiting excessive activin signaling,” Lugovskoy said.HHTWinrevairPAHactivin receptorDiagonal
Diagonal has a good sense of Winrevair's sotatercepts, with Acceleron's former vice president of biology, Patrick Andre, Ph.D., now Diagonal's chief scactivinc officer. Merck got hold of Winrevair when it acquired Acceleron for $11.5 billion in 2021.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。